Physician profile
Allison Hawk
NPI 1396475059
$3,114.76
in general payments reported to CMS, 2019-2025
18 companies · $72.78 in 2025
The $72.78 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $19.54 · 2022: $166 · 2023: $1,996 · 2024: $861 · 2025: $72.78.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,929.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,929.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,198.37 | 2022-2025 | |
| Viiv Healthcare Company | $465.95 | 2023-2024 | Dovato, Apretude |
| Novartis Pharmaceuticals Corporation | $458.04 | 2022-2025 | |
| Gilead Sciences, INC. | $251.49 | 2023-2024 | Sunlenca |
| Novo Nordisk INC | $161.05 | 2023-2024 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $151.09 | 2021-2023 | |
| Glaxosmithkline, LLC. | $107.84 | 2023-2024 | Trelegy Ellipta, Shingrix |
| Merck Sharp & Dohme LLC | $96.04 | 2023-2024 | Verquvo, Belsomra |
| Bayer Healthcare Pharmaceuticals INC. | $40.28 | 2023 | |
| Lilly USA, LLC | $34.05 | 2023 | Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.31 | 2024 | Spiriva Respimat, Stiolto Respimat |
| Exact Sciences Corporation | $21.55 | 2023 | Cologuard Collection Kit |
| Amgen INC. | $21.30 | 2024 | Repatha, Otezla |
| Indivior INC. | $20.90 | 2024 | Sublocade |
| Phathom Pharmaceuticals, INC. | $17.41 | 2024 | Voquezna |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $16.22 | 2024 | Breztri |
| Braeburn INC. | $15.03 | 2024 | Brixadi |
| Janssen Pharmaceuticals, INC | $14.84 | 2023 | Invega Sustenna, Invega Trinza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Hawk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.